Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Biliary tract cancers (BTCs) are aggressive and often diagnosed at advanced stages with poor prognoses.
• Germline or somatic mutations in breast cancer-related gene 1/2 (BRCA1/2) are found in some BTC patients.
• Poly(ADP-ribose) polymerase inhibitors (PARPi) show efficacy with minimal side effects in BRCA-mutant cancers.

Purpose of the Study:

• To review targeted therapies for BRCA-mutant BTCs.
• To highlight differences between germline and somatic BRCA1/2 mutations in BTC.
• To discuss the current landscape and future directions for treating BRCA-mutant BTCs.

Main Methods:

• Literature review of studies on BRCA1/2 mutations in advanced BTC.
• Analysis of treatment outcomes with PARPi and immunotherapy.
• Comparison of germline versus somatic BRCA1/2 mutation impact on therapy response.

Main Results:

• BRCA1/2 mutation frequencies and types vary across studies in advanced BTC.
• Germline BRCA mutations may confer better therapeutic effects than somatic mutations in BTC.
• BRCA-mutated BTC patients show potential benefit from immunotherapy, alone or combined.

Conclusions:

• BRCA1 and BRCA2 mutations have distinct roles in BTC development.
• Targeted therapies, including PARPi, offer a promising avenue for BRCA-mutant BTC.
• Understanding germline vs. somatic BRCA mutations is crucial for optimizing BTC treatment strategies.